Department of Pathology, Division of Microbiology and Immunology, University of Utah School of Medicine, 15 N Medical Dr E, #2100, Salt Lake City, UT 84112, USA.
Clin Infect Dis. 2013 Sep;57(5):719-24. doi: 10.1093/cid/cit284. Epub 2013 May 3.
Acute cystitis is one of the most commonly encountered bacterial infections and is responsible for substantial morbidity and high medical costs in the United States and across the globe. Though generally considered to be self-limiting and easily treated with antibiotics, urinary tract infections (UTIs) are often incompletely resolved by antibiotic therapy and frequently recur. This is in part due to the ability of uropathogenic bacteria to invade, replicate, and persist within host epithelial cells. The biological complexity of these infections combined with a dramatic rise in antibiotic-resistant pathogens highlight the need for alternative therapies. In this review we examine current management strategies for UTIs, as well as emerging treatments, including novel compounds that block bacterial interactions with the urothelium and vaccines focused on preventing both acute and recurrent infections.
急性膀胱炎是最常见的细菌性感染之一,也是造成美国乃至全球发病率高和医疗费用高的主要原因。尽管一般认为其具有自限性,且容易用抗生素治疗,但抗生素治疗通常无法完全解决尿路感染(UTI),而且其经常复发。部分原因是尿路致病性细菌具有侵袭、复制和在宿主上皮细胞内持续存在的能力。这些感染的生物学复杂性以及抗生素耐药病原体的急剧增加突出表明需要替代疗法。在这篇综述中,我们研究了 UTI 的当前治疗策略以及新兴疗法,包括可阻断细菌与尿路上皮相互作用的新型化合物和预防急性和复发性感染的疫苗。